Not applicableStudy completedNCT05894499
What this trial is testing
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Who this might be right for
SARS-CoV-2
ModernaTX, Inc. 13,309